Analyst picks & changes

Amgen Inc.

Piper Jaffray analyst Barbara Hoffman said that trends evident at last week's American Society of Hematology meeting in Nashville bode well for Amgen Inc.

High dose chemotherapy (HDC) is being widely used, she said, despite the fact that

Read the full 390 word article

How to gain access

Continue reading with a
two-week free trial.